Double maintains 1 strategies that include ZNTL - Zentalis Pharmaceuticals, Inc.
Current Value
$1.231 Year Return
Current Value
$1.231 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GCOR | -0.03% | $538.61M | 0.08% |
TLTW | -0.04% | $1.05B | 0.35% |
USDU | -0.06% | $173.33M | 0.5% |
FLMI | 0.07% | $662.09M | 0.3% |
TDTF | -0.08% | $792.63M | 0.18% |
IBDR | -0.10% | $3.26B | 0.1% |
BKAG | 0.14% | $1.86B | 0% |
MINO | -0.15% | $318.17M | 0.39% |
FLIA | 0.16% | $665.81M | 0.25% |
ZROZ | 0.17% | $1.45B | 0.15% |
EDV | 0.18% | $3.41B | 0.05% |
VMBS | -0.19% | $14.33B | 0.03% |
PULS | 0.23% | $11.19B | 0.15% |
DBE | -0.24% | $46.44M | 0.77% |
GSY | -0.25% | $2.77B | 0.22% |
SHAG | -0.26% | $38.03M | 0.12% |
TAXF | -0.26% | $496.10M | 0.29% |
URNM | 0.27% | $1.43B | 0.75% |
EAGG | 0.27% | $3.78B | 0.1% |
TIPZ | -0.27% | $96.29M | 0.2% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 46.94% | $4.85B | 0.35% |
IBB | 46.68% | $5.17B | 0.45% |
GNOM | 45.82% | $39.83M | 0.5% |
ARKG | 45.20% | $914.43M | 0.75% |
BBH | 41.82% | $326.56M | 0.35% |
PBE | 41.04% | $215.67M | 0.58% |
FBT | 39.17% | $1.00B | 0.56% |
IWC | 37.97% | $772.99M | 0.6% |
XPH | 37.54% | $137.67M | 0.35% |
CPRJ | 36.26% | $48.36M | 0.69% |
PTH | 36.09% | $98.02M | 0.6% |
IWM | 35.09% | $63.66B | 0.19% |
VTWO | 35.05% | $12.07B | 0.07% |
IWO | 34.67% | $11.31B | 0.24% |
IWN | 34.45% | $11.00B | 0.24% |
CLOU | 33.91% | $361.77M | 0.68% |
KJUL | 33.89% | $113.06M | 0.79% |
GSSC | 33.63% | $536.87M | 0.2% |
VIOV | 33.59% | $1.26B | 0.1% |
ESML | 33.43% | $1.80B | 0.17% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LU | 0.10% | $2.60B | -30.65% | 0.00% |
DG | -0.13% | $21.59B | -28.77% | 2.34% |
GFI | -0.20% | $19.05B | +26.67% | 2.57% |
NYT | 0.22% | $9.01B | +12.71% | 1.04% |
EXC | -0.28% | $44.81B | +15.42% | 3.50% |
LMT | 0.29% | $110.84B | +1.28% | 2.73% |
SRRK | -0.29% | $2.86B | +140.89% | 0.00% |
TEF | -0.30% | $28.39B | +13.03% | 6.22% |
COKE | -0.38% | $10.16B | +23.23% | 0.68% |
STNG | -0.42% | $2.12B | -49.56% | 3.85% |
HSIC | 0.44% | $8.74B | -2.22% | 0.00% |
BULL | -0.44% | $5.50B | +7.01% | 0.00% |
ED | 0.52% | $37.97B | +9.19% | 3.17% |
AQB | 0.53% | $3.17M | -56.89% | 0.00% |
RLX | 0.55% | $1.78B | -1.51% | 0.49% |
ASTH | 0.80% | $1.34B | -31.26% | 0.00% |
TIMB | 0.80% | $8.38B | +6.18% | 2.99% |
LNG | -0.81% | $51.72B | +45.94% | 0.83% |
DOGZ | 0.82% | $276.89M | +164.60% | 0.00% |
PSN | 0.84% | $7.30B | -11.40% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
NGNE | 46.81% | $278.40M | -42.61% | 0.00% |
CRBU | 44.32% | $97.65M | -66.45% | 0.00% |
ARCT | 41.06% | $325.18M | -60.69% | 0.00% |
RCKT | 39.66% | $694.91M | -71.75% | 0.00% |
KYMR | 39.37% | $1.97B | -16.13% | 0.00% |
IDYA | 38.99% | $1.58B | -55.16% | 0.00% |
FATE | 38.98% | $139.85M | -68.80% | 0.00% |
ADPT | 38.93% | $1.40B | +156.27% | 0.00% |
INMD | 38.63% | $1.01B | -23.53% | 0.00% |
CRSP | 38.56% | $3.34B | -30.27% | 0.00% |
BEAM | 38.55% | $1.78B | -28.93% | 0.00% |
CERS | 37.85% | $252.33M | -32.31% | 0.00% |
LAW | 37.73% | $240.19M | -39.42% | 0.00% |
CGEM | 37.71% | $455.00M | -67.85% | 0.00% |
GSAT | 37.67% | $2.33B | +2.11% | 0.00% |
IMNM | 37.53% | $696.97M | -41.96% | 0.00% |
KOD | 37.33% | $195.75M | +13.80% | 0.00% |
COGT | 37.24% | $567.00M | -36.48% | 0.00% |
GPRO | 37.13% | $95.32M | -61.22% | 0.00% |
PGEN | 37.00% | $401.44M | -2.16% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TAIL | -23.44% | $140.64M | 0.59% |
VIXY | -22.27% | $116.60M | 0.85% |
BTAL | -21.75% | $361.71M | 1.43% |
ULST | -16.13% | $632.05M | 0.2% |
IVOL | -12.68% | $353.50M | 1.02% |
XHLF | -10.80% | $1.46B | 0.03% |
SPTS | -10.67% | $5.74B | 0.03% |
IBTH | -10.15% | $1.53B | 0.07% |
YEAR | -10.07% | $1.40B | 0.25% |
BILS | -10.01% | $3.95B | 0.1356% |
KCCA | -9.81% | $95.62M | 0.87% |
GBIL | -9.75% | $6.16B | 0.12% |
VGSH | -9.49% | $22.36B | 0.03% |
SMB | -9.36% | $269.27M | 0.07% |
IBTJ | -9.33% | $662.50M | 0.07% |
FXY | -9.27% | $850.17M | 0.4% |
STPZ | -9.25% | $452.72M | 0.2% |
IBTG | -8.99% | $1.89B | 0.07% |
SHYM | -8.67% | $323.00M | 0.35% |
XONE | -8.60% | $608.48M | 0.03% |
Yahoo
Zentalis Pharmaceuticals ( NASDAQ:ZNTL ) First Quarter 2025 Results Key Financial Results Net loss: US$48.3m (down from...
Yahoo
First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback $332.5 million cash, cash equivalents and marketable securities supports operational runway into late 2027 SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a pote
Finnhub
SAN DIEGO - Zentalis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and...
Yahoo
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on May 1, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 14,000 shares of the Company’s common stock to one (1) newly hired employee.
Yahoo
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Yahoo
Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced tha
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MSIF | -16.21% | $753.44M | +35.28% | 6.67% |
CMTL | -15.82% | $59.28M | -19.52% | 0.00% |
LITB | -12.99% | $22.07M | -71.93% | 0.00% |
VHC | -12.47% | $35.49M | +75.53% | 0.00% |
CBOE | -11.59% | $23.50B | +22.83% | 1.09% |
K | -9.85% | $28.59B | +32.73% | 2.75% |
FMTO | -7.84% | $46.19M | -99.95% | 0.00% |
STG | -6.71% | $28.09M | -38.64% | 0.00% |
CL | -6.12% | $74.35B | -2.81% | 2.19% |
MNOV | -5.99% | $68.66M | +2.19% | 0.00% |
CME | -5.56% | $100.16B | +31.56% | 3.79% |
FATBB | -5.34% | $49.18M | -12.37% | 10.15% |
FMC | -4.53% | $5.00B | -37.37% | 5.76% |
MKTX | -4.39% | $8.23B | +1.72% | 1.35% |
LZB | -3.87% | $1.80B | +21.98% | 1.93% |
KMB | -3.85% | $46.72B | +5.37% | 3.49% |
HRB | -3.81% | $7.77B | +8.86% | 2.51% |
COR | -3.48% | $56.72B | +32.41% | 0.73% |
CNK | -3.22% | $3.64B | +79.07% | 0.25% |
KR | -2.98% | $45.58B | +27.96% | 1.84% |